Treat DVT with Low Molecular Weight Heparin

Cheryl Nadeau, Jerry Varrone

Research output: Contribution to journalArticle

Abstract

Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalization to receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalNurse Practitioner
Volume28
Issue number10
StatePublished - 2003

Fingerprint

Social Adjustment
Low Molecular Weight Heparin
Pulmonary Embolism
Venous Thrombosis
Anticoagulants
Heparin
Hospitalization
Pharmacokinetics
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)

Cite this

Treat DVT with Low Molecular Weight Heparin. / Nadeau, Cheryl; Varrone, Jerry.

In: Nurse Practitioner, Vol. 28, No. 10, 2003, p. 22-29.

Research output: Contribution to journalArticle

Nadeau, C & Varrone, J 2003, 'Treat DVT with Low Molecular Weight Heparin', Nurse Practitioner, vol. 28, no. 10, pp. 22-29.
Nadeau, Cheryl ; Varrone, Jerry. / Treat DVT with Low Molecular Weight Heparin. In: Nurse Practitioner. 2003 ; Vol. 28, No. 10. pp. 22-29.
@article{f4464d388d1244a48eae58bd54369cb4,
title = "Treat DVT with Low Molecular Weight Heparin",
abstract = "Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalization to receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.",
author = "Cheryl Nadeau and Jerry Varrone",
year = "2003",
language = "English (US)",
volume = "28",
pages = "22--29",
journal = "Nurse Practitioner",
issn = "0361-1817",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Treat DVT with Low Molecular Weight Heparin

AU - Nadeau, Cheryl

AU - Varrone, Jerry

PY - 2003

Y1 - 2003

N2 - Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalization to receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.

AB - Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalization to receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.

UR - http://www.scopus.com/inward/record.url?scp=85026162677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026162677&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 22

EP - 29

JO - Nurse Practitioner

JF - Nurse Practitioner

SN - 0361-1817

IS - 10

ER -